Pfizer Extends Commitment to Help Unemployed Americans

Pfizer Inc.Pfizer will extend its MAINTAIN™ (Medicines Assistance for Those who Are in Need) patient assistance program for an additional year, through December 31, 2010. In addition to the more than 70 Pfizer primary care medicines currently available through MAINTAIN, Pfizer will extend the benefits of MAINTAIN to many legacy Wyeth medicines.

Pfizer launched MAINTAIN in May to help unemployed and uninsured Americans stay on their Pfizer medicines. The program, an employee-driven initiative, is part of Pfizer Helpful Answers®, Pfizer's family of patient assistance programs that helps uninsured and underinsured Americans get Pfizer medicines for free or at a savings. Seventy-five percent of people who have applied to Pfizer’s MAINTAIN program have been enrolled.

Coupled with testimonials from MAINTAIN members and other interactive features, Pfizer released the MAINTAIN widget, an online tool that guides users through a short series of questions that determine whether they may be eligible for MAINTAIN or for another Pfizer patient assistance program.

Gail Grime, a MAINTAIN member from Ohio, lost her employment and health insurance after a 23-year career working for a U.S.-based auto parts manufacturer. Ms. Grime learned about MAINTAIN in a newspaper article, which she has subsequently shared with her family and many of her former co-workers.

"When I lost my job, I found myself without medical coverage for the first time in years. But thanks to MAINTAIN, I don't have to cut back on my Pfizer medicines, or go without them," Ms. Grime said. "The application was easy but, most importantly, the folks in customer service answered every one of my questions. In these rough times, it’s nice to have someone looking out for you."

By extending the benefits of the MAINTAIN program for another year and to patients needing help with legacy Wyeth medicines, Pfizer is responding to the continued economic challenges facing hard-working Americans. Although the economy appears to be on the mend and the number of job losses has begun to slow, data show that unemployment remains at a 26-year high.

"In the last year, we have witnessed a great deal of suffering. Yet, our families, friends and neighbors have exhibited true American spirit, finding innovative ways to manage during tough times," said Jorge Puente, Pfizer's regional president of Worldwide Pharmaceuticals and a leading champion of the initiative. "Signs are pointing to recovery; however, millions of people are struggling without the benefit of insurance and without a regular income. As the world's largest biopharmaceutical company, we believe we have a corporate responsibility to help our fellow Americans who need the medicines Pfizer offers, but who do not have insurance to help pay for them. By extending MAINTAIN, we are hopeful that we can continue to relieve some of the burden created by the recession."

Pfizer has long been a leader in making medicines accessible to uninsured Americans, and MAINTAIN is just the latest example of Pfizer's innovation in the area of improved access. In 2004, the company expanded Pfizer Helpful Answers, the company's family of patient assistance programs, becoming the first pharmaceutical company to help anyone in the United States without prescription insurance, no matter their age or income.

Pfizer Helpful Answers has been helping uninsured and underinsured patients get Pfizer medicines for free or at a savings for more than two decades. In the last five years alone, Pfizer has helped more than 5 million uninsured patients get access to more than 51 million Pfizer prescriptions valued at more than $4.8 billion at wholesale cost through its patient assistance programs. The reach of Pfizer's patient assistance programs in each state is illustrated in one of the charts accompanying this release.

"Pfizer MAINTAIN is a response to the evolving needs of uninsured Americans. Access programs are, simply put, ingrained in our corporate culture," Puente said.

MAINTAIN Eligibility Requirements and Application
The MAINTAIN program has four eligibility requirements. Applicants must:

  • Be able to demonstrate loss of employment on or after January 1, 2009;
  • Lack prescription coverage;
  • Attest to financial need; and,
  • Have been on their Pfizer medicine for at least three months prior to unemployment and enrolling in the program.

The program is user-friendly, with a one-page application that Pfizer will typically process within two to three weeks. Applicants may download the one-page application from www.PfizerHelpfulAnswers.com, or request one by calling 866-706-2400, where live operators can help callers find out if they may be eligible for one of Pfizer's patient assistance programs.

The program will accept applications through December 31, 2010. If eligible for MAINTAIN, patients can get their medicines for free for up to one year after enrollment or until they become insured, whichever comes first. People who are uninsured and still need help after being on MAINTAIN for a year can apply to one of Pfizer's other patient assistance programs.

For Help with Wyeth Medicines
As a result of Pfizer and Wyeth coming together, Pfizer is also extending the benefits of MAINTAIN to people who need help staying on their Wyeth primary care medicines. Until the Pfizer and Wyeth patient assistance programs are fully integrated, likely by mid-2010, please visit www.PfizerHelpfulAnswers.com and click on the Wyeth link or call 866-706-2400 and ask for help with Wyeth medicines.

About Pfizer Helpful Answers®
Pfizer Helpful Answers is a family of patient assistance programs for the uninsured and underinsured who need help getting Pfizer medicines. Today, it is the largest and most extensive set of patient assistance programs in the United States. Pfizer Helpful Answers provides Pfizer medicines for free or at a savings to patients who qualify. Some programs also offer reimbursement support services for people with insurance. Pfizer Helpful Answers is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™.

About Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Most Popular Now

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...

Pfizer reaches a global agreement with AbbVie

Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under ...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

GSK reaches agreement to acquire TESARO, an oncolo…

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...